When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Soleno Therapeutics just met that criteria with a new score of 83.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest runs.
Soleno Therapeutics has climbed more than 5% past a 60.92 entry in a fourth-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% EPS growth in the latest quarterly report. Sales increased 0%.
Soleno Therapeutics earns the No. 41 rank among its peers in the Medical-Products industry group. Insulet, LivaNova and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
